Streetbeat News

FWBI

First Wave BioPharma Inc

https://www.azurrx.com/

CEO

James Sapirstein

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Open

2.93

Mkt cap

Volume

56K

High

3.04

P/E Ratio

-0.06

52-wk high

60.00

Low

2.84

Div yield

N/A

52-wk low

2.33

During Wednesday's pre-market session, several healthcare stocks experienced significant movements. Gainers included 60 Degrees (SXTP), Panbela Therapeutics (PBLA), Bio-Path Hldgs (BPTH), bluebird bio (BLUE), Zynerba Pharmaceuticals (ZYNE), and Prenetics Global (PRE). Losers included Amarin Corp (AMRN), ZyVersa Therapeutics (ZVSA), Dynatronics (DYNT), Biophytis (BPTS), First Wave BioPharma (FWBI), and Milestone Pharmaceuticals (MIST).

Portfolio Pulse from Benzinga Insights

July 19, 2023 | 1:06 pm

First Wave BioPharma has announced the pricing of its public offering of 3.285 million shares of its common stock at $0.64 per share, aiming to raise $2.1 million.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2023 | 12:19 pm

During Tuesday's trading, 46 companies set new 52-week lows. The largest company by market cap to set a new 52-week low was TELUS (NYSE:TU). American Rebel Holdings (NASDAQ:AREB) was the smallest firm on a market cap basis to set a new 52-week low. 9 Meters Biopharma (NASDAQ:NMTR) was the biggest loser, trading down 68.25% to reach its 52-week low. Shuttle Pharmaceuticals (NASDAQ:SHPH) saw the sharpest rebound, as shares ascended 0.0%, reversing after hitting a new 52-week low.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 5:47 pm

The article lists the stocks that gained and lost the most in Tuesday's mid-day session. Some of the gainers include Pieris Pharmaceuticals, The Singing Machine Company, Biophytis, iCAD, Aridis Pharmaceuticals, and The Charles Schwab Corporation. The losers include 9 Meters Biopharma, Fangdd Network Group, Lixte Biotechnology Holdings, Masimo Corporation, and Aptevo Therapeutics.

Portfolio Pulse from Lisa Levin

July 18, 2023 | 5:00 pm

During Tuesday's pre-market session, several healthcare stocks experienced significant movements. Biophytis, Aridis Pharmaceuticals, Hyperfine, Karyopharm Therapeutics, Genprex, and Lantern Pharma saw increases in their share prices, while 9 Meters Biopharma, Lixte Biotech Hldgs, Masimo, CEL-SCI, EUDA Health Holdings, and First Wave BioPharma experienced declines.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:06 pm

Biophytis S.A. (BPTS) shares surged 53.9% after signing a partnership with SEQENS to produce Sarconeos (BIO101) active compound. Aridis Pharmaceuticals, Inc. (ARDS) shares gained 41.8% after EMA announced positive feedback on the company's proposed Phase 3 study AR-301. Karyopharm Therapeutics Inc. (KPTI) rose 26.1% after receiving FDA Fast Track Designation for Selinexor for Myelofibrosis. 9 Meters Biopharma, Inc. (NMTR) fell 59% and Masimo Corporation (MASI) fell 27.3% after reporting weak preliminary revenue results for Q2.

Portfolio Pulse from Lisa Levin

July 18, 2023 | 12:12 pm

In Monday's after-market session, several health care stocks saw significant movement. Aridis Pharmaceuticals (ARDS), Dare Bioscience (DARE), Karyopharm Therapeutics (KPTI), Cue Health (HLTH), Cardio Diagnostics Hldgs (CDIO), and Petros Pharma (PTPI) all saw gains, with ARDS leading with an 89.5% increase. On the other hand, 9 Meters Biopharma (NMTR), Masimo (MASI), CEL-SCI (CVM), EUDA Health Holdings (EUDA), First Wave BioPharma (FWBI), and Acumen Pharmaceuticals (ABOS) all experienced losses, with NMTR falling by 60%.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 9:32 pm

HC Wainwright & Co. analyst Yi Chen has downgraded First Wave BioPharma from Buy to Neutral.

Portfolio Pulse from richadhand@benzinga.com

July 14, 2023 | 10:15 am

PepsiCo Inc reported better-than-expected Q2 results and raised FY23 outlook, leading to a positive impact on its stock. Energy shares fell by 0.9% while communication services shares climbed by 2.4%. Stocks of Jiuzi Holdings, Nikola Corporation, and Camtek Ltd rose significantly. However, Viasat, Cryoport, and First Wave BioPharma stocks fell due to various reasons.

Portfolio Pulse from Lisa Levin

July 13, 2023 | 6:39 pm

During Thursday's intraday session, several healthcare stocks experienced significant movements. Gainers included Bicycle Therapeutics (BCYC), Applied DNA Sciences (APDN), EyePoint Pharmaceuticals (EYPT), AVITA Medical (RCEL), Exicure (XCUR), and CytoMed Therapeutics (GDTC). Losers included First Wave BioPharma (FWBI), Healthcare Triangle (HCTI), CryoPort (CYRX), Eloxx Pharmaceuticals (ELOX), Generation Bio (GBIO), and Rockwell Medical (RMTI).

Portfolio Pulse from Benzinga Insights

July 13, 2023 | 5:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.